Much has changed in the 10 years since our first survey of industry researchers. Large companies are now looking to small, nimble ones for services as well as innovation.
Advertisement
The Scientist
Most Recent
Major pharmaceutical companies have agreed to a handful of recommendations aimed at increasing the transparency of clinical trials they fund.
Human-specific duplications of a gene involved in brain development may have contributed to our species’ unique intelligence.
Human embryonic stem cells swiftly kill themselves in response to DNA damage.
Genes that react to cellular sugar content are regulated by a long non-coding RNA via an unexpected mechanism
From accounts of deformed animals to scratch-and-sniff technology, Robert Boyle's early contributions to the Royal Society of London were prolific and wide ranging.
During development, the cells of an embryo change their pattern of gene expression, which allows them to detach from their original location and migrate to another part of the embryo, where the pattern changes again to allow formation of a new organ.
A flood of new discoveries has refined our definition of cancer stem cells. Now it’s up to human clinical trials to test if they can make a difference in patients.
GlaxoSmithKline and Johnson & Johnson contribute a total of $100 million to early-stage biotech endeavors.
Pharmaceutical companies should deploy cash to fund struggling biotech companies, which could generate much needed new drugs.
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
